Fall Private Company Showcase 2021-Solebury Trout, BMO

Chameleon Presents at Solebury Trout Fall Private Company Showcase 2021

November 5, 2021

Genine Winslow, CEO and Founder of Chameleon Biosciences, was invited to present at the 8th Annual Virtual Solebury Trout Fall Private Company Showcase. This selective, annual showcase highlights new and emerging biotechs. Ms. Winslow shared exciting preclinical data on Chameleon’s proprietary next generation AAV-based vectors which are designed to overcome the immune response related challenges of current AAV gene therapies. See the slides and more.

Read More >

Chameleon Biosciences at CureDuchenne’s National “FUTURES” Conference

October 1, 2021

Genine Winslow, CEO and Founder of Chameleon Biosciences will be participating in a panel discussion at the upcoming CureDuchenne’s National “FUTURES” Conference.

Read More >

EVADER™ – stealth mode, next-generation AAV-based gene therapy vectors

September 23, 2021

Chameleon Biosciences is developing next-generation adeno-associated virus vectors that elicit minimal immune responses, allowing repeat dosing and resulting in superior efficacies. These EVADER vectors have universal application for existing adeno-associated virus vectors, and Chameleon is seeking partners to advance its lead program in severe hemophilia B.

Read More >